Adaptive Biotechnologies is trading 4.1% up at $24.05 as investors continue to respond to its July 29 earnings report, which featured strong MRD revenue growth and a raised full-year guidance range.
- The company's updated outlook for its Minimal Residual Disease (MRD) business has bolstered investor confidence in its long-term growth trajectory.
- The move aligns with a broader rally in the biotech sector, with the XBI ETF and major U.S. indices trending higher.
- Positive market sentiment toward healthcare and growth names is reinforcing the upward momentum for the stock.